Navigation Links
CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
Date:7/25/2012

PRINCETON, New Jersey, July 25, 2012 /PRNewswire/ --

CitiusTech Inc., a leading provider of healthcare technology services and solutions, announced its results for the half year ended 30 June 2012. Revenues grew by 65% compared with the equivalent period in 2011. CitiusTech now has over 850 employees worldwide and serves half of the top 20 technology organizations in healthcare.

In H1 2012, CitiusTech expanded its software product engineering business and developed strong capabilities in new healthcare initiatives (Meaningful Use Stage 2, ACOs, Payment Reforms and HIEs) and emerging technologies (BI/Analytics, mobile health and cloud computing). With close to 400 HL7 certified healthcare interoperability professionals, CitiusTech professional services group retains the unique distinction of having the highest number of HL7 certified professionals worldwide. CitiusTech expanded its operational presence through a new software delivery center at Mindspace Airoli.

BI-Clinical, CitiusTech's leading platform for healthcare BI and Analytics, today supports over 1,200 provider facilities - the largest deployment of a third-party ONC-ATCB 2011/2012 certified BI/Analytics solution in the US market. BI-Clinical now supports complete cloud-based deployment including clinical quality measures for ACO, PQRS, HEDIS and Meaningful use initiatives.

CitiusTech received the 'Best Places to Work 2012' Award by the Great Places to Work Institute, the world's leading human resources consulting, research and training firm. CitiusTech has recently been invited to join the prestigious CHIME Foundation.

"2012 is emerging as a pivotal year for the healthcare IT industry," CitiusTech's Chief Executive Officer, Rizwan Koita, said, "In addition to managing our accelerated business growth, we have established strong partnerships with leading healthcare organizations. We continue to invest heavily in R&D - key for our next phase of growth".

About Ci
'/>"/>

SOURCE CitiusTech Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Addus HomeCare Announces Second Quarter 2012 Earnings Release and Conference Call
2. PDI, Inc. Announces $29 Million in New and Extended Sales Contracts
3. Vibra Healthcare Announces Agreement To Manage Two Acute Rehabilitation Hospitals
4. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
5. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
6. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
8. Egalet Announces Issuance of U.S. Patent
9. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
10. Sancilio and Company Announces New Directors
11. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... report on Form 20-F for the year ended ... and Exchange Commission (the "SEC"). The annual report ...
... Mindray Medical International Limited (NYSE: MR ), ... worldwide, announced today that it has filed with the ... 20-F that included audited financial statements for the year ... Annual Report on Form 20-F is available on Mindray,s ...
Cached Medicine Technology:ShangPharma Corporation Files 2011 Annual Report on Form 20-F 2Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... , , , ... of revenue and payment cycle management solutions for the ... Illinois, recently implemented the Emdeon Patient Responsibility Estimator(SM) solution. ... used by BroMenn,s patient access staff to inform patients ...
... , SAN ANTONIO, Aug. 24 Fall 2009 ... in family schedules, which can have a devastating impact on family pets ... season. PurinaCare(R) Pet Health Insurance ( www.purinacare.com ), which is committed to ... urging all pet owners to be aware of the signs of post-summer ...
... , , , ... VRX ) today announced preliminary results from its ... pain associated with postherpetic neuralgia (PHN), a painful and common complication ... did not meet its pre-specified primary efficacy endpoint. Further detailed analyses ...
... WACO, Texas, Aug. 24 Two professors at ... health care plan in their new book Health Care for ... University Press, that does not create a government entitlement program ... care of Americans who currently have coverage. , , ...
... WASHINGTON, Aug. 24 What did all the following businessmen have in common? , ... Merv Griffin (TV Producer) , Tom Witter ... , , They all died from the prostate cancer, ... son, father or grandfather will die from this disease. , , Hank ...
... NANJING, China, Aug. 24 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... leading manufacturer and supplier,of branded generic and innovative pharmaceuticals ... University Cancer Center. , Located ... of,China,s renowned cancer research institutions, prominent in pre-clinical and,clinical ...
Cached Medicine News:Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 2Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 3Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 4Health News:Does Your Pet Have Post-Summer Separation Anxiety? 2Health News:Does Your Pet Have Post-Summer Separation Anxiety? 3Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 2Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 3Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 4Health News:Baylor University Economists Call for Different Tack on Health Care Insurance 2Health News:Prostate Cancer Kills - Every 20 Minutes; September Is Prostate Cancer Awareness Month 2Health News:Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center 2
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Severe revision options for the knee and hip...
The Precedent establishes a new generation of revision hip stems....
Medicine Products: